At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIAF bioAffinity Technologies, Inc.
Post-Mkt 03-17 18:39:27 EDT
2.74
+0.83
+43.46%
盘后2.59
-0.15-5.47%
18:39 EDT
High3.09Low2.23Vol124.12M
Open2.23D1 Closing1.91Amplitude45.03%
Mkt Cap12.33MTradable Cap9.32MTotal Shares4.50M
T/O334.69MT/O Rate3,649.21%Tradable Shares3.40M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Why Is bioAffinity Technologies Stock Surging Tuesday?
Benzinga_recent_news  ·  03-17 22:32
Why Is bioAffinity Technologies Stock Surging Tuesday?
bioAffinity Technologies releases CyPath Lung case study highlighting 92% sensitivity in nodules under 20 mm
Reuters  ·  03-17 19:45
bioAffinity Technologies releases CyPath Lung case study highlighting 92% sensitivity in nodules under 20 mm
BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio
Reuters  ·  03-14
BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
Benzinga  ·  03-13
bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth
bioAffinity Technologies FY2025 net loss widens 66% to USD 14.91 million on revenue down 34% to USD 6.16 million
Reuters  ·  03-13
bioAffinity Technologies FY2025 net loss widens 66% to USD 14.91 million on revenue down 34% to USD 6.16 million
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic Cypath® Lung
THOMSON REUTERS  ·  03-13
bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic Cypath® Lung
BioAffinity Technologies initiates clinical study for CyPath Lung
TIPRANKS  ·  03-10
BioAffinity Technologies initiates clinical study for CyPath Lung
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive Cypath® Lung Cancer Diagnostic
THOMSON REUTERS  ·  03-10
bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive Cypath® Lung Cancer Diagnostic
bioAffinity Technologies directors Robert Anderson and Roby Joyce to step down at April 30 annual meeting
Reuters  ·  03-07
bioAffinity Technologies directors Robert Anderson and Roby Joyce to step down at April 30 annual meeting
bioAffinity Technologies reports positive findings for asthma therapy-matching sputum diagnostic platform
Reuters  ·  03-03
bioAffinity Technologies reports positive findings for asthma therapy-matching sputum diagnostic platform
BRIEF-Bioaffinity Announces Validation Study For Lung Cancer Test
Reuters  ·  02-25
BRIEF-Bioaffinity Announces Validation Study For Lung Cancer Test
bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study
Reuters  ·  02-25
bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study
bioAffinity Technologies Announces Validation Study With Brooke Army Medical Center to Expand SAMPLE Collection Options for the Cypath® Lung Noninvasive Early Detection Lung Cancer Test
THOMSON REUTERS  ·  02-25
bioAffinity Technologies Announces Validation Study With Brooke Army Medical Center to Expand SAMPLE Collection Options for the Cypath® Lung Noninvasive Early Detection Lung Cancer Test
bioAffinity Technologies Highlights CyPath Lung Case Study Supporting Noninvasive Lung Cancer Surveillance
Reuters  ·  02-20
bioAffinity Technologies Highlights CyPath Lung Case Study Supporting Noninvasive Lung Cancer Surveillance
bioAffinity Technologies Showcases CyPath Lung Test Clinical Utility in Real-World Case Study
Reuters  ·  02-17
bioAffinity Technologies Showcases CyPath Lung Test Clinical Utility in Real-World Case Study
BioAffinity Technologies announces new appointments to Advisory Board
TIPRANKS  ·  02-09
BioAffinity Technologies announces new appointments to Advisory Board
bioAffinity Technologies Expands Advisory Board With Leading Lung Cancer Experts
Reuters  ·  02-09
bioAffinity Technologies Expands Advisory Board With Leading Lung Cancer Experts
bioAffinity Technologies’ Precision Pathology Laboratory Services Maintains CAP Accreditation
Reuters  ·  01-07
bioAffinity Technologies’ Precision Pathology Laboratory Services Maintains CAP Accreditation
bioAffinity Technologies' Precision Pathology Laboratory Services Finalizes Succession with Dr. Humphreys as New Owner
Reuters  ·  2025-12-23
bioAffinity Technologies' Precision Pathology Laboratory Services Finalizes Succession with Dr. Humphreys as New Owner
bioAffinity Technologies Showcases CyPath Lung Test Success in Early Lung Cancer Detection at NLCRT
Reuters  ·  2025-12-03
bioAffinity Technologies Showcases CyPath Lung Test Success in Early Lung Cancer Detection at NLCRT

Introduction

Company Name.
bioAffinity Technologies, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Issue price:
--